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Abstract Dithiothreitol (DTT) treatment of angiotensin II
(Ang II) type 2 (AT2) receptor potentiates ligand binding, but
the underlying mechanism is not known. Two disulfide bonds
proposed in the extracellular domain were examined in this
report. Based on the analysis of ligand affinity of cysteine (Cys,
C) to alanine (Ala, A) substitution mutants, we provide evidence
that Cys35^Cys290 and Cys117^Cys195 disulfide bonds are formed
in the wild-type AT2 receptor. Disruption of the highly conserved
Cys117^Cys195 disulfide bond linking the second and third
extracellular segments leads to inactivation of the receptor.
The Cys35^Cys290 bond is highly sensitive to DTT. Its breakage
results in an increased binding affinity for both Ang II and the
AT2 receptor-specific antagonist PD123319. Surprisingly, in the
single Cys mutants, C35A and C290A, a labile population of
receptors is produced which can be re-folded to high-affinity state
by DTT treatment. These results suggest that the free ^SH group
of Cys35 or Cys290 competes with the disulfide bond formation
between Cys117 and Cys195. This Cys^disulfide bond exchange
results in production of the inactive population of the mutant
receptors through formation of a non-native disulfide
bond. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Di¡erential susceptibility to dithiothreitol (DTT) is a hall-
mark for distinguishing two classes of receptors for the octa-
peptide hormone angiotensin II (Ang II). The Ang II receptor
family which includes the type 1 (AT1) and the type 2 (AT2)
receptors is a group of heptahelical receptors. They are char-
acterized by a single polypeptide chain containing seven trans-
membrane helices (TMI^TMVII) linked by four extracellular
and four cytoplasmic segments [1^9]. The DTT-inactivated
AT1 receptor selectively binds biphenyl imidazole compounds
such as losartan and its structural analogues. The DTT-po-
tentiated AT2 receptor binds imidazole pyridine carboxylic
acid compounds such as PD123319. Both AT1 and AT2 re-
ceptors have been shown to activate G-protein-mediated in-
tracellular signal transduction [1^7].
The covalent linking of the TMIII and the second extracel-
lular loop through a disul¢de bridge is thought to be impor-
tant for generation and stabilization of the receptor structure
in the entire G-protein-coupled receptor (GPCR) superfamily
[10^18]. Mutation of these cysteines (Cys, C) or reduction of
the disul¢de linkage between them impairs the function, for
instance in rhodopsin [12,13], L-adrenergic receptors [14,15]
and muscarinic receptors [16] through ultimate destabilization
of the TM bundle. The DTT inactivation^activation of Ang II
receptor therefore must be governed by a similar structure^
function principle. Through a mutagenesis study, Ohyama et
al. [17] demonstrated that the rat AT1 receptor contains two
disul¢de bonds in the extracellular domain, and that both the
disul¢de bonds are essential to maintain high a⁄nity of AT1
receptor for Ang II. However, the mechanism of potentiation
of AT2 receptor by DTT is not elucidated.
The AT2 receptor presents several unusual properties. It
was originally identi¢ed as a DTT-potentiated receptor that
activated intracellular signal transduction pathways independ-
ent of G-protein coupling [4,18,19]. Molecular cloning led to
identi¢cation of structural features of a GPCR in the deduced
AT2 receptor-polypeptide and recent studies indicate its abil-
ity to couple to G-proteins [4^6]. DTT-potentiation was a
signi¢cant property of the AT2 receptor that aided the devel-
opment of a subtype-selective non-peptide antagonist well
ahead of molecular cloning of the receptor cDNA [1]. Expres-
sion of this receptor is re-activated at the sites of healing skin
wound, infarcted myocardium and injured vascular tissue
where the redox potential may be in favor of reduction of
disul¢de bonds [18^20]. Hence, structure^function studies di-
rected to understand DTT-potentiation of AT2 receptor are
clearly important. In this study, we investigated the structural
basis of DTT-potentiation of the Ang II binding a⁄nity of
wild-type and mutant rat AT2 receptors (Fig. 1 ) expressed in
COS1 cells. We report here that disruption of interaction be-
tween Cys35 and Cys290 located in the putative extracellular
domain of the AT2 receptor is responsible for a generalized
potentiation of ligand binding. When Cys35 and Cys290 resi-
dues are unpaired, reversible inactivation occurs in speci¢c
mutants through the formation of a non-native disul¢de
bond.
2. Materials and methods
2.1. Materials
The monoclonal antibody 1D4 was supplied by the Cell Culture
Center, Endotronic Inc. (Minneapolis, MN, USA). Oligonuclides
were obtained from the oligonuclide synthesis core facility of the
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Research Institute, The Cleveland Clinic Foundation. Ang II,
[Sar1]Ang II, [Sar1,Ile8]Ang II, and Ang III were obtained from Bach-
em. 125I-[Sar1,Ile8]Ang II was supplied by Dr. Robert Speth, Univer-
sity of Washington, Pulman, WA, USA. The speci¢c activity of the
125I-[Sar1,Ile8]Ang II was 2200 Ci/mmol. Losartan was a gift from
DuPont Merck (Wilmington, DE, USA). PD123319 was purchased
from RBI, Natick, MA, USA. 3H-Losartan was from Amersham.
DTT and other chemicals were from Sigma (St. Louis, MO, USA).
2.2. Cloning, mutagenesis and expression of Ang II receptors
The synthetic rat AT1 receptor gene, cloned in the shuttle expres-
sion vector pMT3, was used for expression as described earlier [21^
25]. The cDNA of AT2 receptor was cloned from mRNA isolated
from adrenal medulla of SHR rat by reverse transcriptase coupled
polymerase chain reaction. The cloned cDNA was fully sequenced
and modi¢ed for expression in COS1 cells by: (1) To contain a con-
sensus Marilyn^Kozak sequence and a unique EcoRI site at the 5P end
and NotI site at the 3P end of the gene. (2) To encode an octapeptide
(ETSQVAPA) epitope for a monoclonal antibody 1D4 at the 3P end
before the stop codon. The epitope-tagged cDNA was subcloned into
a shuttle vector pMT3 in which the cDNA would be transcribed from
a polyoma major late promoter. Mutant AT2 receptors were prepared
by the restriction fragment replacement method and the polymerase
chain reaction method. DNA sequence analysis was done to con¢rm
each mutant construct. For expression of receptor proteins, 10 Wg of
CsCl-puri¢ed plasmid DNA per 107 cells was used in transfection.
COS1 cells (American Type Culture Collection, Rockville, MD,
USA), cultured in Dulbecco’s modi¢ed minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum, were trans-
fected by the DEAE^dextran method. Transfected cells cultured for
72 h were harvested. Cell membranes were prepared by the nitrogen
par bomb disruption method and suspended in HME bu¡er (50 mM
HEPES, pH 7.2, 12.5 mM MgCl2, 1.5 mM EGTA) containing 10%
glycerol as described earlier [21^25]. The receptor expression was as-
sessed in each case by immunoblot analysis and by 125I-[Sar1,Ile8]Ang
II saturation binding analysis.
2.3. Western blot of receptors expressed in COS1 cells
Post-nuclear supernatant of COS1 cells solubilized in lysis bu¡er
(50 mM Tris^HCl, pH 6.8, 1% CHAPS, 5 mM EDTA, pH 8.0) con-
taining 50 Wg/ml PMSF and centrifuged at 40 000 rpm was used for
SDS^PAGE and Western blotting analysis. Receptor polypeptides
were visualized using 2.5 Wg/ml of mouse monoclonal antibody 1D4
and the alkaline phosphatase conjugated anti-mouse IgG antibody
(Promega, Corp., Madison, WI, USA). The membrane was exposed
to X-ray ¢lm (Kodak) at 370‡C. The relative intensities of the bands
were estimated by phosphorimager analysis.
2.4. DTT treatment
Membrane preparations containing receptor protein were mixed
with assay bu¡er (50 mM sodium phosphate, pH 7.2, 100 mM
NaCl, 10 mM MgCl2, 1 mM EGTA, 0.2% bovine serum albumin,
and 10 Wg/ml bacitracin) containing various concentrations of DTT
(0^100 mM) at 22‡C for 20 min. Pretreated membranes were used
for equilibrium binding studies. To examine the e¡ect of ligand oc-
cupancy, membrane preparations were preincubated with either
125I-[Sar1,Ile8]Ang II or 3H-losartan in assay bu¡er for 40 min at
22‡C and then treated with various concentrations of DTT at 22‡C
for 20 min. Then binding study was performed. In recovery studies,
DTT-treated membrane preparations were washed three times in cold
assay bu¡er without DTT and then used for binding study (also see
[14,15]).
2.5. Ligand binding study
The ligand binding experiments were carried out under equilibrium
conditions as described before [14,21^25]. Brie£y, membranes express-
ing receptors were incubated with 0.03^3 nM 125I-[Sar1,Ile8]Ang II in
assay bu¡er for competition binding study. For saturation binding
study, an at least 10-fold higher concentration of 125I-[Sar1,Ile8]Ang
II than the Kd value of the receptor was used in order to get s 90%
bound form of added receptor. The highest concentration of
125I-[Sar1,Ile8]Ang II is diluted by half to make 8^12 di¡erent concen-
trations to facilitate the Scatchard plot analysis. Non-speci¢c binding
Fig. 1. A secondary structure model of the rat AT2 receptor. The location of 14 cysteine residues is indicated in the proposed membrane topol-
ogy. Five cysteines conserved between AT1 and AT2 receptors are shown in circles and the proposed disul¢de interactions in the extracellular
domain are indicated. Potential glycosylation sites and the octapeptide^epitope tag used in the immunoblotting experiments are shown.
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to the membranes was determined from 125I-[Sar1,Ile8]Ang II binding
in the presence of 1035 M cold 127I-[Sar1,Ile8]Ang II. All binding
studies were performed at 22‡C for 1 h unless speci¢cally indicated.
The binding reaction was stopped by ¢ltering under vacuum (Brandel
Type M-24R) on FP-200 GF/C ¢lters (Whatman Inc., Fair¢eld, NJ,
USA). Filter-bound 125I-[Sar1,Ile8]Ang II was quantitated in a gam-
ma-counter (Packard). Equilibrium binding kinetics were determined
using the computer program Ligand or Scatchard plot. The Kd values
represent the mean þ S.E.M. of three or more independent determina-
tions.
3. Results
3.1. The experimental system
The epitope-tagged AT2 receptors were expressed in COS1
cells by transient transfection. In total membrane preparation
obtained from the transfected cells, the expression of AT2
receptor was detected by immunoblotting (Fig. 2). The ex-
pressed AT2 receptor displayed high a⁄nity (Kd, 1 þ 0.25
nM) binding for the peptide analogue 127I-[Sar1,Ile8]Ang II,
(Table 1). The Bmax values measured was W4.2 pmol/mg.
Scatchard plot analysis of the 125I-[Sar1,Ile8]Ang II saturation
binding indicated a single a⁄nity class of receptors (not
shown). Competition binding studies employing Ang II,
[Sar1]Ang II, [Sar1,Ile8]Ang II, Ang III, PD123319 (AT2 se-
lective) and Losartan (AT1 selective), demonstrated that the
receptors expressed in COS1 cells preserve the selectivity and
a⁄nity pro¢le previously described for native tissue receptors
as well as recombinantly expressed receptors. Thus, we con-
clude that high level expression of AT2 receptors leads to the
formation of a unique a⁄nity state of the receptor. Expres-
sion and characterization of AT1 receptor in COS1 cells has
been described earlier [21^24]. Thus COS1 cell transient trans-
fection is a suitable system for structure^function analysis of
AT2 receptor.
3.2. E¡ect of Ala substitution of extracellular Cys residues
To assign the putative disul¢de interaction in the AT2 re-
ceptor and to evaluate their contribution to receptor confor-
mation, four single and two double Cys to Ala substitution
mutants were constructed. Immunoblot analysis indicated
nearly comparable levels of expression of the wild-type and
all the six mutants in COS1 cells (Fig. 2). Binding a⁄nity of
the C117A and C195A mutants for all ligands was signi¢-
cantly reduced (s 10 000-fold, see Table 1). The double mu-
tant, C117A^C290A also produced a s 10 000-fold decrease
in ligand binding that is consistent with the phenotype of
C117A mutant but not that of C290A implying that these
residues are not partners in a disul¢de bond. In sharp contrast
the C35A and C290A single mutants displayed a gain of af-
¢nity for both peptide and the non-peptide ligands. The phe-
notype of the C35A^C290A double mutant is consistent with
the phenotype of the two single mutants.
3.3. E¡ect of DTT treatment of wild-type AT2 receptor on
ligand binding
Treatment with 5 mM DTT potentiated binding of
125I-[Sar1,Ile8]Ang II to AT2 receptors in COS1 membranes.
The same treatment abolished binding to AT1 receptor in
COS1 membranes consistent with published reports on native
receptors [2^7]. Fig. 3A shows the e¡ect of various concen-
trations of DTT on 125I-[Sar1,Ile8]Ang II binding to similar
levels of wild-type AT1 and AT2 receptors in COS1 mem-
branes. The binding to AT2 receptors increased by 60% at
4^6 mM DTT concentration. At s 8 mM DTT concentra-
tion, the AT2 receptor was gradually inactivated. The mid-
point of the potentiation phase corresponds to W0.4 mM
DTT and the mid-point of the inactivation phase corresponds
to W40 mM DTT. The potentiating e¡ect was signi¢cantly
attenuated in the presence of [Sar1,Ile8]Ang II but not in the
presence of losartan or inactive Ang II analogues. Under
identical conditions DTT treatment inactivated AT1 receptor
completely at s 2 mM DTT concentration. Presence of
[Sar1,Ile8]Ang II and losartan signi¢cantly attenuated, but
non-binding analogues of Ang II and PD123319 did not pro-
tect AT1 receptor against DTT inactivation.
The potentiation of binding to the AT2 receptor is predom-
Fig. 2. Immunoblot analysis of the wild-type and mutant AT2
receptors expressed in COS1 cells. All receptors were detected by
utilizing a monoclonal antibody, 1D4, recognizing the epitope
TETSQVAPA attached at the C-terminus in each case. The Bmax
values corresponding to the protein band are shown without DTT
treatment and with DTT treatment. ud: Binding undetectable.
Table 1
Binding a⁄nity of wild-type and mutant receptors pretreated with and without 5 mM DTT at 22‡C for 20 min
Without DTT pretreatment With DTT pretreatment
[Sar1,Ile8]Ang II Ang II PD123319 [Sar1,Ile8]Ang II Ang II PD123319
Ki (nM) -fold Ki (nM) -fold Ki (nM) -fold Ki (nM) -fold Ki (nM) -fold Ki (nM) -fold
AT1 WT 0.3 þ 0.09 ND 3.6 þ 0.41 ND s 1 000 s 1 000 ND
AT2 WT 1.0 þ 0.25 1.9 þ 0.32 17.2 þ 2.2 0.1 þ 0.02 0.7 þ 0.12 2.1 þ 0.43
C35A 0.1 þ 0.01 310 0.4 þ 0.11 34.8 1.77 þ 0.5 39.7 0.1 þ 0.01 1 0.3 þ 0.02 32.3 1.7 þ 0.37 31.2
C117A s 10 000 10 000 s 10 000 1 400 s 10 000 600 s 10 000 10 000 s 10 000 10 000 s 10 000 5 000
C195A s 10 000 10 000 s 10 000 1 400 s 10 000 600 s 10 000 10 000 s 10 0000 10 000 s 10 000 5 000
C290A 0.1 þ 0.01 310 0.3 þ 0.08 36.3 1.86 þ 0.5 39.3 0.1 þ 0.01 1 0.3 þ 0.02 32.3 1.7 þ 0.41 31.2
C35A^C290A 0.1 þ 0.01 310 0.3 þ 0.08 36.3 1.51 þ 0.3 311.4 0.1 þ 0.01 1 0.4 þ 0.06 31.8 1.4 þ 0.36 31.5
C117A^C290A s 10 000 10 000 s 10 000 1 400 s 10 000 600 s 10 000 10 000 s 10 000 10 000 s 10 000 5 000
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inantly a result of a W10-fold increase in a⁄nity for peptide
ligands and W8-fold increase of a⁄nity for PD123319 with
no signi¢cant change in Bmax (Table 1 and Fig. 2). The rever-
sibility of the DTT-induced conformational changes was ex-
amined. The membranes were treated with DTT for 20 min
and DTT was removed by washing. The recovery of the native
state of the AT2 receptor was estimated from the change in
distribution from high and normal a⁄nity receptors by
Scatchard plot analysis. Removal of DTT led to nearly
100% reversal to normal a⁄nity state (1 nM) in the AT2
receptor. In complete contrast, the inactivation of AT1
receptor by DTT is predominantly due to loss of binding
sites (Bmax) rather than a decrease of binding a⁄nity.
The Bmax decreased upon DTT treatment from 5.1 to 0.72
pmol/mg. Nearly 70% of the Bmax was recovered upon re-
moval of DTT (data not shown). At high concentrations
of DTT (s 40 mM), AT2 receptor inactivation involved
loss of Bmax. Thus, both AT1 and AT2 receptors appear to
refold to normal a⁄nity conformation upon removal of
DTT.
3.4. E¡ect of DTT treatment on mutant AT2 receptor on ligand
binding
In order to assign the disul¢de bond responsible for the
DTT-induced potentiation of the AT2 receptor, DTT-induced
potentiation of ligand a⁄nity was examined in various Cys to
Ala mutants. The data presented in Table 1 indicate that the
DTT-induced a⁄nity increase is absent in mutants C35A,
C290A and C35A-C290A. More importantly, these three mu-
tants exhibit 8^10-fold higher a⁄nity for all ligands than the
wild-type receptor without DTT potentiation. This observa-
tion suggested to us that breakage of Cys35^Cys290 disul¢de
bond alone is responsible for the DTT-potentiation of AT2
receptor.
We then examined if breakage of the C35^C290 disul¢de
bond would change the kinetics of reduction of the C117^
C195 disul¢de bond. In the double mutant C35A^C290A,
the DTT-potentiation was completely absent and DTT-inacti-
vation was similar to the inactivation of wild-type AT2 recep-
tor (Fig. 3B). Thus, the two disul¢de bonds in the AT2 re-
ceptor have completely independent roles.
3.5. Reversible inactivation of C35A and C290A mutant
receptors by Cys^disul¢de bond exchange
Despite comparable levels of polypeptide expression, the
measured Bmax values for the single mutants, C35A and
C290A were consistently lower than that for the wild-type
and the C35A^C290A mutant. Furthermore, the Bmax was
sensitive to storage speci¢cally in these two mutants. We sys-
tematically analyzed this phenomenon in an experiment. The
mutant membranes were kept at 4‡C for 24 h. The Bmax de-
creased by 60 and 30% respectively in the C35A and the
C290A mutants. Scatchard plot analysis revealed that the de-
crease of Bmax was not due to conversion of the receptor to a
low a⁄nity state, but due to loss of binding sites. Rather
surprisingly, treatment of C35A and C290A mutants with
5 mM DTT led to a dramatic increase in binding of 125I-
[Sar1,Ile8]Ang II in both C35A and C290A mutants (see
Fig. 3B). In contrast, the double mutant C35A^C290A, and
the wild-type AT2 receptors did not exhibit this phenomenon.
DTT treatment did not lead to regain of binding sites in the
C117A^C290A defective mutant. The inactivation phase, of
the binding pro¢le is preserved in C35A and C290A mutants
at s 10 mM DTT, implying that all of the refolded receptors
contain the conserved C117^C195 disul¢de bond which is
sensitive to a high concentration of DTT.
4. Discussion
The rat AT2 receptor contains 14 Cys residues. 10 Cys
residues located in the transmembrane and cytoplasmic do-
Fig. 3. E¡ect of varying concentrations of DTT on 125I-
[Sar1,Ile8]Ang II binding to AT1 and AT2 receptors. The speci¢c
binding of 125I-[Sar1,Ile8]Ang II in each sample was adjusted to be
6 10 þ 1% (W20 000) of total input CPM without any treatment.
This value is represented as 100%. A: Binding to wild-type AT1
and AT2 receptors. Open symbols refer to samples exposed to DTT
after 20 min exposure to ligand and closed symbol refers to samples
exposed to DTT ¢rst and then ligand was added. B: Binding to
wild-type and mutant AT2 receptors in membranes pretreated with
DTT.
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main are not likely to be involved in disul¢de bonds (see Fig.
1). The remaining four Cys residues, Cys35, Cys117, Cys195,
and Cys290 are located in the extracellular domain where the
redox environment may facilitate two disul¢de bonds. System-
atic mutation of these four Cys residues showed two di¡erent
phenotypes of AT2 receptor. The ¢rst, observed in the single
C117A or C195A mutants and also in the C117A^C290A
double mutant is characterized by non-detectable binding of
analogues of Ang II. The polypeptide expression is not re-
duced in these mutants. Also, treatment with 5 mM DTT
did not restore ligand binding. The observations suggest
that a disul¢de bond between Cys117 and Cys195 in the extra-
cellular domain is critical for the polypeptide to gain ligand
binding conformation and in its absence the polypeptide is
irreversibly misfolded. The active conformation is believed
to require a compact structure involving proper alignment
of TM helices and the connecting loops, which is stabilized
by the critical disul¢de linkage [12^17]. The results also sug-
gest that if a Cys35^Cys195 disul¢de bond is formed in the
C117A^C290A mutant, then such a bond cannot substitute
for the conserved disul¢de bond. The inactivation of the wild-
type AT2 receptor at high concentrations of DTT, must in-
volve reduction of this disul¢de linkage.
The second phenotype is an increase in a⁄nity for all li-
gands, observed in the C35A, C290A and the C35A^C290A
mutants. The most characteristic feature of these three mu-
tants is the absence of DTT-potentiation. These mutant phe-
notypes indicate that Cys35 and Cys290 are linked in a disul¢de
bond which is responsible for the DTT-potentiation phenom-
enon in the wild-type AT2 receptor. Thus, the TM domain
stability and strengths of the Cys35^Cys290 and Cys117^Cys195
S^S bonds are directly coupled. This explains the bell shape of
the DTT action curve for the AT2 receptor (Fig. 3). Attenu-
ation of the DTT e¡ect on both these disul¢de bonds in the
presence of peptide and subtype-selective non-peptide ligands
suggests that occupation of the pocket protects against desta-
bilization. In other GPCRs the bound ligands have been
found to protect the receptor from reducing e¡ects of DTT
[14^16]. In L-adrenergic receptors, through reconstitution in
lipid membranes, Pederson and Ross [15] demonstrated that
at low concentrations DTT activated the receptor, but at
higher concentrations led to inactivation. Noda et al. [14]
have assigned distinct disul¢de bonds responsible for each
phase of DTT.
Because C35A and C290A mutant polypeptides are capable
of folding to active receptor conformation, we reason that the
free ^SH group in either C35A or C290A mutant does not
interfere with normal membrane insertion and alignment of
transmembrane helices to form a binding pocket. We specu-
late that the unpaired ^SH group in each case is the cause of
destabilization of the folded conformational state of the mu-
tant receptors through disul¢de formation with either the free
Cys residues in TM domain or through interference with the
conserved C117^C195 disul¢de bond. A non-native disul¢de
bond thus formed in both C35A and C290A mutant receptors
could destabilize the Ang II binding state of the receptor.
Since the evidence presented above indicates that C117^
C195 disul¢de is critical for this conformation, it seems
most likely that breakage of the C117^C195 disul¢de bond
is the cause for gradual loss of Bmax in the C35A and
C290A mutants. This speculation is also supported by the
DTT-reactivation in the inactive membrane preparations,
although disul¢de bond formation with a di¡erent Cys other
than these two is also expected to be reversible. Thus, regain
of ligand a⁄nity from DTT treatment in both C35A and
C290A mutants is consistent with a Cys disul¢de bond ex-
change leading to reformation of the conserved disul¢de
bond. If the inactivation was due to interaction with a non-
Cys residue, such an interaction is usually weak, hardly could
be destabilizing and is not expected to be reversed by DTT. It
is generally believed that the highly conserved disul¢de bond
is relatively stable and its breakage could lead to unfolding of
the receptor. Unfolding of proteins usually results in denatur-
ation, which is followed by an irreversible process, most often
aggregation [10^15]. For instance, the irreversible inactivation
of C117A, C195A and C117A^C290A mutant receptors could
be the result of such unfolding. In the case of mutant C35A
and C290A mutants, protection against irreversible inactiva-
tion might be a¡orded by the non-native S^S bond. A Cys
disul¢de exchange reaction has been described previously, in
the generation of active rhodopsin from opsin fragments [26].
To the best of our knowledge, this is the ¢rst demonstration
of recti¢cation of a misfolded GPCR mutant by reduction of
a non-native disul¢de bond which prevented irreversible inac-
tivation through unfolding reactions.
The in vivo physiological signi¢cance of DTT-mediated po-
tentiation of AT2 receptor is presently unknown. Indeed in
many pathophysiological conditions such as vascular injury
and wound healing where local redox potential may favor
disul¢de reduction [1^7,18^20], a regulatory mechanism for
AT2 receptor potentiation may involve disruption of the
Cys35^Cys290 bond. Recently, an intermolecular disul¢de
bridge formed as part of dimerization in metabotropic gluta-
mate receptors and the calcium sensing receptor has been
demonstrated [27,28]. A similar mechanism has been discov-
ered for activation of the OxyR transcription factor by revers-
ible disul¢de bond formation [29]. Certain diseases associated
with GPCR malfunction are caused by introduction of un-
paired Cys residues in the extracellular domain. For instance,
a disproportionate number of mutations that cause nephro-
genic diabetes are single Cys substitutions in the extracellular
loop 2 of V2 vasopressin receptor. A retinitis pigmentosa mu-
tation involves a Cys substitution in the extracellular loop 2 in
human rhodopsin [10,12,13,26]. A Cys disul¢de exchange re-
action, such as the one described above, may be the cause of
inactivation^disfunction in these mutant receptors leading to
disease states.
Cys residues are found quite frequently in GPCRs, where
they play quite di¡erent structure^function roles. In the trans-
membrane segments the Cys residues are mostly free with no
particular preference in facing lipid or interior of the protein
[10^17]. In the cytoplasmic tail one or more Cys residues are
palmitoylated. The most conserved disul¢de bridge in the
extracellular domain links the TMIII with extracellular loop
2 in several GPCRs. In bovine rhodopsin, this bond helps
stabilize interaction of a part of the extracellular loop with
the ligand, 11-cis-retinal [30]. Mutational analysis has demon-
strated a reciprocal relationship between stabilities of this di-
sul¢de bond and the ligand pocket formed by the TM bundle
in rhodopsin, L-adrenergic receptor and the AT1 receptor.
Additional Cys residues are found in the extracellular domain
of a number of other GPCRs which may form a second di-
sul¢de linkage. Substitution of these Cys residues in AT1,
chemokine CXCR1 and CCR-2 receptors seriously impairs
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agonist binding, but in bradykinin B2 receptor and NPY Y1
receptor substitution has no e¡ect [10,11].
In summary, we report that the unpaired Cys35 and Cys290
residues in the AT2 receptor lead to an inactive population of
mutant receptors that could be recti¢ed through a thiol sensi-
tive step. We also show that the Cys35^Cys290 disul¢de bond
confers DTT potentiation and the Cys117^Cys195 disul¢de
bond confers stability in the AT2 receptor.
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